- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.11. | Biodesix-Direktor Jack Schuler kauft Aktien im Wert von 122.840 US-Dollar | 1 | Investing.com Deutsch | ||
| 22.11. | Biodesix-Direktor Kennedy Lawrence T. Jr erwirbt Aktien im Wert von 40.561 US-Dollar | 2 | Investing.com Deutsch | ||
| 21.11. | Biodesix Inc-Direktor Jack Schuler kauft Aktien im Wert von 234.000 US-Dollar | 1 | Investing.com Deutsch | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 20.11. | BDSX stock touches 52-week low at $1.15 amid market challenges | 2 | Investing.com | ||
| 13.11. | Biodesix-Chefbuchhalter verkauft Aktien im Wert von 283 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.11. | Entwicklungsleiter von Biodesix verkauft Aktien für 595 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.11. | Biodesix CFO Robin Harper Cowie verkauft Aktien im Wert von 1.355 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.11. | Biodesix-CEO Scott Hutton verkauft Aktien im Wert von 5.219 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.11. | Biodesix-Vertriebsleiter verkauft Aktien im Wert von 644 US-Dollar | 1 | Investing.com Deutsch | ||
| 06.11. | Biodesix-Direktor Massarany erwirbt Stammaktien im Wert von 30.865 US-Dollar | 1 | Investing.com Deutsch | ||
| 06.11. | Biodesix-Vorstandsvorsitzender John Patience erwirbt Aktien im Wert von 103.710 US-Dollar | 1 | Investing.com Deutsch | ||
| 06.11. | Biodesix-Direktor Kennedy Lawrence T. Jr. erwirbt Aktien im Wert von 97.068 US-Dollar | 1 | Investing.com Deutsch | ||
| 06.11. | Biodesix-Direktor Matthew Strobeck erwirbt Aktien im Wert von 55.915 US-Dollar | 2 | Investing.com Deutsch | ||
| 06.11. | Biodesix-Direktor Jack Schuler kauft Aktien im Wert von 136.000 US-Dollar | 2 | Investing.com Deutsch | ||
| 04.11. | Biodesix, Inc. (NASDAQ:BDSX) Q3 2024 Earnings Call Transcript | 3 | Insider Monkey | ||
| 01.11. | Biodesix GAAP EPS of -$0.07 beats by $0.01, revenue of $18.2M misses by $0.32M | 1 | Seeking Alpha | ||
| 01.11. | Biodesix, Inc.: Biodesix Announces Third Quarter 2024 Results and Highlights | 128 | GlobeNewswire (Europe) | Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast... ► Artikel lesen | |
| 24.09. | Farallon Capital Management LLC Purchases New Stake in Biodesix, Inc. (NASDAQ:BDSX) | 1 | MarketBeat | ||
| 15.08. | BIODESIX INC - 8-K, Current Report | - | SEC Filings | ||
| 13.08. | Biodesix CFO sells over $1,500 in company stock | 1 | Investing.com |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,000 | -95,74 % | Paion Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,428 | +29,70 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,240 | 0,00 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,660 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,700 | -0,38 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| GUARDANT HEALTH | 31,370 | 0,00 % | Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance | PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.
Third Quarter... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,000 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,930 | +2,42 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,900 | 0,00 % | Assertio Holdings, Inc.: Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study | LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,890 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 6,060 | 0,00 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,420 | +0,54 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,780 | 0,00 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,305 | +9,27 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen |
BIODESIX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,460 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.
